|
1
|
Kammori M, Fukumori T, Sugishita Y, Hoshi
M and Yamada T: Therapeutic strategy for low-risk thyroid cancer in
Kanaji Thyroid Hospital. Endocr J. 61:1–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roti E, Rossi R, Trasforini G, Bertelli F,
Ambrosio MR, Busutti L, Pearce EN, Braverman LE and Degli Uberti
EC: Clinical and histological characteristics of papillary thyroid
microcarcinoma: Results of a retrospective study in 243 patients. J
Clin Endocrinol Metab. 91:2171–2178. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tang W, Huang C, Tang C, Xu J and Wang H:
Galectin-3 may serve as a potential marker for diagnosis and
prognosis in papillary thyroid carcinoma: A meta-analysis. Onco
Targets Ther. 9:455–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Isic Dencic T, Cvejic D, Paunovic I, Tatic
S, Havelka M and Savin S: Cytokeratin19 expression discriminates
papillary thyroid carcinoma from other thyroid lesions and predicts
its aggressive behavior. Med Oncol. 30:3622013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American Thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pacini F: Thyroid microcarcinoma. Best
Pract Res Clin Endocrinol Metab. 26:421–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giannini R, Faviana P, Cavinato T, Elisei
R, Pacini F, Berti P, Fontanini G, Ugolini C, Camacci T, De Ieso K,
et al: Galectin-3 and oncofetal-fibronectin expression in thyroid
neoplasia as assessed by reverse ranscription-polymerase chain
reaction and immunochemistry in cytologic and pathologic specimens.
Thyroid. 13:765–770. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheung CC, Ezzat S, Freeman JL, Rosen IB
and Asa SL: Immunohistochemical diagnosis of papillary thyroid
carcinoma. Mod Pathol. 14:338–342. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kreft A, Hansen T and Kirkpatrick CJ:
Thyroid transcription factor 1 expression in cystic lesions of the
neck: An immunohistochemical investigation of thyroglossal duct
cysts, branchial cleft cysts and metastatic papillary thyroid
cancer. Virchows Arch. 447:9–11. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McLeod DS, Sawka AM and Cooper DS:
Controversies in primary treatment of low-risk papillary thyroid
cancer. Lancet. 381:1046–1057. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Patron V, Bedfert C, Le Clech G, Aubry K
and Jegoux F: Pattern of lateral neck metastases in N0 papillary
thyroid carcinoma. BMC Cancer. 11:82011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hartl DM, Leboulleux S, Al Ghuzlan A,
Baudin E, Chami L, Schlumberger M and Travagli JP: Optimization of
staging of the neck with prophylactic central and lateral neck
dissection for papillary thyroid carcinoma. Ann Surg. 255:777–783.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pazaitou-Panayiotou K, Capezzone M and
Pacini F: Clinical features and therapeutic implication of
papillary thyroid microcarcinoma. Thyroid. 17:1085–1092. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chow SM, Law SC, Chan JK, Au SK, Yau S and
Lau WH: Papillary microcarcinoma of the thyroid-prognostic
significance of lymph node met astasis and multifocality. Cancer.
98:31–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim TY, Hong SJ, Kim JM, Kim WG, Gong G,
Ryu JS, Kim WB, Yun SC and Shong YK: Prognostic parameters for
recurrence of papillary thyroid microcarcinoma. BMC Cancer.
8:2962008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fisher ER, Palekar AS, Sass R and Fisher
B: Scar cancers: Pathologic findings from the national surgical
adjuvant breast project (protocol no. 4)-IX. Breast Cancer Res
Treat. 3:39–59. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang C, Fu L, Fu J, Hu L, Yang H, Rong
TH, Li Y, Liu H, Fu SB, Zeng YX and Guan XY: Fibroblast growth
factor receptor 2-positive fibroblasts provide a suitable
microenvironment for tumor development and progression in
esophageal carcinoma. Clin Cancer Res. 15:4017–4027. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hwang RF, Moore T, Arumugam T,
Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB and Logsdon CD:
Cancer-associated stromal fibroblasts promote pancreatic tumor
progression. Cancer Res. 68:918–926. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kozel PJ, Friedman RA, Erway LC, Yamoah
EN, Liu LH, Riddle T, Duffy JJ, Doetschman T, Miller ML, Cardell EL
and Shull GE: Balance and hearing deficits in mice with a null
mutation in the gene encoding plasma membrane
Ca2+-ATPase isoform. J Bio Chem. 273:18693–18696. 1998.
View Article : Google Scholar
|
|
20
|
Nazareth MR, Broderick L, Simpson-Abelson
MR, Kelleher RJ Jr, Yokota SJ and Bankert RB: Characterization of
human lung tumor-associated fibroblasts and their ability to
modulate the activation of tumor-associated T cells. J Immunol.
178:5552–5562. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kondo T, Okabayashi K, Hasegawa H, Tsuruta
M, Shigeta K and Kitagawa Y: The impact of hepatic fibrosis on the
incidence of liver metastasis from colorectal cancer. Br J Cancer.
115:34–39. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen X, Xiao W, Chen W, Liu X, Wu M, Bo Q,
Luo Y, Ye S, Cao Y and Liu Y: MicroRNA-26a and −26b inhibit lens
fibrosis and cataract by negatively regulating Jagged-1/Notch
signaling pathway. Cell Death Differ. 24:1431–1442. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miura K, Hamanaka K, Koizumi T, Kitaguchi
Y, Terada Y, Nakamura D, Kumeda H, Agatsuma H, Hyogotani A,
Kawakami S, et al: Clinical significance of preoperative serum
albumin level for prognosis in surgically resected patients with
non-small cell lung cancer: Comparative study of normal lung,
emphysema, and pulmonary fibrosis. Lung Cancer. 111:88–95. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Isarangkul W: Dense fibrosis. Another
diagnostic criterion for papillary thyroid carcinoma. Arch Pathol
Lab Med. 117:645–666. 1993.PubMed/NCBI
|
|
25
|
Livolsi VA and Saavedra JA: Papillary
carcinoma. DeLellis RA, Lloyd RV, Heitz PU and Eng C: World Health
Organization Classification of Tumours: Pathology and Genetics of
Tumours of Endocrine Organs. 8. IARC Press; Lyon, France: pp.
57–66. 2004
|
|
26
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual andthe future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kumar V, Donthireddy L, Marvel D,
Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P,
Behera R, Goins MA, et al: Cancer-associated fibroblasts neutralize
the anti-tumor effect of CSF1 receptor blockade by inducing
PMN-MDSC infiltration of tumors. Cancer Cell. 32:654–668.e5. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sewell-Loftin MK, Bayer SVH, Crist E,
Hughes T, Joison SM, Longmore GD and George SC: Cancer-associated
fibroblasts support vascular growth through mechanical force. Sci
Rep. 7:125742017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pang T, Wang X, Gao J, Chen W, Shen XJ,
Nie MM, Luo T, Yin K, Fang G, Wang KX and Xue XC: Fiber-modified
hexon-chimeric oncolytic adenovirus targeting cancer associated
fibroblasts inhibits tumor growth in gastric carcinoma. Oncotarget.
8:76468–76478. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tao L, Huang G, Song H, Chen Y and Chen L:
Cancer associated fibroblasts: An essential role in the tumor
microenvironment. Oncol Lett. 14:2611–2620. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang J, Wang Y, Li D and Jing S: Notch
and TGF-β/Smad3 pathways are involved in the interaction between
cancer cells and cancer-associated fibroblasts in papillary thyroid
carcinoma. Tumour Biol. 35:379–385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Van den Eynden GG, Colpaert CG, Couvelard
A, Pezzella F, Dirix LY, Vermeulen PB, Van Marck EA and Hasebe T: A
fibrotic focus is a prognostic factor and a surrogate marker for
hypoxia and (lymph)angiogenesis in breast cancer: Review of the
literature and proposal on the criteria of evaluation.
Histopathology. 51:440–451. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rebecchini C, Nobile A, Piana S, Sarro R,
Bisig B, Gerasimos SP, Saglietti C, Matter M, Marino L and
Bongiovanni M: Papillary thyroid carcinoma with fibromatosis-like
stroma: Are port of two cases. Endocr Pathol. 13:219–221. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mujtaba SS, Ni YB, Tsang JY, Chan SK,
Yamaguchi R, Tanaka M, Tan PH and Tse GM: Fibrotic focus in breast
carcinomas: Relationship with prognostic parameters and biomarkers.
Ann Surg Oncol. 20:2842–2849. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou H, Kimura K, Orita T, Nishida T and
Sonoda KH: Inhibition by female sex hormones of collagen
degradation by corneal fibroblasts. Mol Vis. 17:3415–422.
2011.PubMed/NCBI
|
|
36
|
De Matos PS, Ferreira AP, de Oliveira
Facuri F, Assumpção LV, Metze K and Ward LS: Usefulness of HBME-1,
cytokeratin 19 and galectin-3 immunostainingin the diagnosis of
thyroid malignancy. Histopathology. 47:391–401. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Htwe TT, Karim N, Wong J, Jahanfar S and
Mansur MA: Differential expression of galectin-3 in advancing
thyroid cancer cells: A clue toward understanding tumour
progression and metastasis. Singapore Med J. 51:856–859.
2010.PubMed/NCBI
|
|
38
|
Erkılıç S, Aydın A and Koçer NE:
Diagnostic utility of cytokeratin 19 expression in multinodular
goiter with papillary areas and papillary carcinoma of thyroid.
Endocr Pathol. 13:207–211. 2002. View Article : Google Scholar : PubMed/NCBI
|
